| 刘 尧,刘 畅,刘月平.乳腺癌抗HER2治疗的耐药机制研究进展及对策[J].肿瘤学杂志,2022,28(5):349-354. |
| 乳腺癌抗HER2治疗的耐药机制研究进展及对策 |
| Mechanism of Resistance to HER2 Therapy of Breast Cancer and Countermeasures |
| 投稿时间：2022-02-22 |
| DOI：10.11735/j.issn.1671-170X.2022.05.B002 |
|
 |
| 中文关键词: 乳腺癌 人表皮生长因子受体2 靶向治疗 耐药机制 |
| 英文关键词:breast cancer human epidermal growth factor receptor 2 targeted therapy drug resistance mechanism |
| 基金项目: |
|
| 摘要点击次数: 945 |
| 全文下载次数: 203 |
| 中文摘要: |
| 摘 要：人表皮生长因子受体2（human epidermal growth factor receptor 2，HER2）阳性乳腺癌是乳腺癌侵袭性较强的类型，其预后差且复发率高。约1/3乳腺癌为HER2阳性乳腺癌，HER2蛋白的表达水平明显较高。HER2作为一个重要的生物标志物，是制定治疗策略的理想靶点，但内在性耐药和获得性耐药是一个重大挑战。许多针对抗HER2治疗的潜在抵抗机制，包括HER2信号通路的不完全阻断、阻断HER2下游信号通路以及免疫耐药机制等会导致HER2途径或其下游信号传导的再激活。近年来，一系列新型的抗HER2药物已进入临床试验的各个阶段。然而，关于选择最合适的抗HER2靶向治疗药物的问题仍然存在，这也在一定程度上阻碍了新的生物标志物和靶向治疗药物的问世。深入了解HER2的耐药机制对于制定进一步改善患者预后的策略至关重要。全文对HER2靶向治疗的耐药机制进行了阐述，并介绍可能解决耐药途径的对策。 |
| 英文摘要: |
| Abstract： Human epidermal growth factor receptor 2(HER2) positive breast cancer accounts for one third of breast cancer， which is highly invasive and has poor prognosis and high recurrence rate. HER2 is an ideal target for developing treatment strategies， but intrinsic and secondary drug resistance is a major challenge. There are various mechanisms involved in drug resistance， incomplete blocking of HER2 signal pathway， blocking of HER2 downstream signal pathway or immune mechanism would lead to the reactivation of HER2 pathway or its downstream signal transduction. In recent years， a series of new anti-HER2 drugs have entered clinical trials. However， the selection of the most suitable anti-HER2 drugs is still a problem， which hinders the advent of new biomarks and targeted therapy drugs. Therefore in-depth understanding of the mechanism of HER2 resistance is conducive to the strategies of developing new anti-HER2 drugs. In this article， the drug resistance mechanisms of HER2 targeted therapy are reviewed， and the possible countermeasures are discussed. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |